SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate up ...

SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")), and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin"), today announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM 1) mutation to the U.S. Food and Drug Administration (FDA) on March 31, 2025. Ziftom ...

About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory ("R/R") NPM1-mutan ...

– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract containing preclinic ...

Kura Oncology (NASDAQ: KURA ) is a pharmaceutical company best known for being one of the pioneers in a novel form of targeted therapy that is currently causing a major stir among researchers inI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. Securities registered pursuant to 12(g) of the Act: None Indicate by check mark if the registrant is a well ...

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Azar - Stifel Charles Zhu - LifeSci Capital David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Operator Go ...

CORPORATE PRESENTATION Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer February 2025 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, KO-2806 and tipifarnib, plans regarding regulatory filings, our expectations regarding the relative benefits o ...

Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 65.08%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.64 per share when it actually produced a loss of $0.63, delivering a surprise of 1.56%.Over the last four quarters, the compa ...

Core Insights - Kura Oncology's KOMET-001 registrational trial for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) achieved its primary endpoint, paving the way for a New Drug Application (NDA) submission in the upcoming quarter [2][3] - The company has reached alignment with the FDA and EMA on the KOMET-017 trial protocol, which includes the use of minimum residual disease (MRD)-negative complete response (CR) as a primary endpoint for potential accelerated approval in the U.S. [2][3] - Kura Oncology reported a cash position of $727.4 million, which, along with anticipated collaboration payments, is expected to support the commercialization of ziftomenib through frontline AML combination settings [1][7] Clinical Development - The KOMET-001 trial demonstrated a targeted complete response (CR) rate of 20-30%, with positive topline results submitted for presentation at ASCO [3] - The KOMET-017 trial is set to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy regimens, with topline results anticipated in 2028 [1][2] - Positive clinical data from the Phase 1 trial (KOMET-007) showed that 91% of patients achieved a CR when ziftomenib was combined with standard treatments [3][4] Financial Performance - Collaboration revenue for the fourth quarter and full year 2024 was $53.9 million, compared to no revenue in 2023 [6] - Research and development (R&D) expenses for Q4 2024 were $52.3 million, up from $32.5 million in Q4 2023, while full-year R&D expenses reached $170.0 million compared to $115.2 million in the prior year [6] - The net loss for Q4 2024 was $19.2 million, a decrease from a net loss of $42.8 million in Q4 2023, with a full-year net loss of $174.0 million compared to $152.6 million in 2023 [6][14] Strategic Collaborations - Kura Oncology entered a global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, retaining leadership and strategic rights in the U.S. [6][10] - The collaboration aims to fund an expansive AML development program through U.S. commercialization in first-line combinations [6][10] Future Milestones - The company plans to submit an NDA for ziftomenib in R/R NPM1-mutant AML in Q2 2025 and present topline data from the KOMET-001 trial in the same timeframe [11] - Initiation of the KOMET-015 trial evaluating ziftomenib and imatinib in advanced gastrointestinal stromal tumors (GIST) is expected in the first half of 2025 [11] - Two independent Phase 3 trials for first-line intensive and non-intensive AML are anticipated to start in the second half of 2025 [11]